

THREE CASES WITH FAMILIAL SHORT STATURE: LERI-WEILL SYNDROME



İlkay Ayrancı¹, Gönül Çatlı², Berna Eroğlu Filibeli¹, Hayrullah Manyas¹, Yaşar Bekir Kutbay³, Altuğ Koç³, Bumin Dünder²

¹University of Health Sciences İzmir Tepecik Training and Research Hospital, Department of Pediatric Endocrinology

²İzmir Kâtip Çelebi University Faculty of Medicine, Department of Pediatric Endocrinology

³University of Health Sciences İzmir Tepecik Training and Research Hospital, Genetic Diseases Diagnosis Center




Introduction

- ❖ *SHOX* gene is located in pseudoautosomal regions of chromosomes Xp22.33 and Yp11.32
- ❖ Loss of both *SHOX* alleles is defined as Langer's mesomelic dysplasia (severe type)
- ❖ Loss of one *SHOX* allele is defined as Leri-Weil syndrome (moderate type)
- ❖ Heterozygous missense mutations in *SHOX* allele cause idiopathic short stature (mild type)
- ❖ rhGH treatment is safe and effective in improving final height in children with *SHOX* deficiency.

In this report, we present clinical features and responses to rhGH treatment of three cases with Leri-Weil syndrome who were being followed-up for familial short stature.

Cases

Clinical and laboratory features of three cases with Leri-Weil syndrome are summarized in **Table 1**.



Madelung Deformity



Tablo 1. Clinical and laboratory features of three cases diagnosed with Leri-Weill syndrome

	CASE-1	CASE-2	CASE-3
Age	6.2	3.6	1.6
Sex	Male	Male	Female
Complaints	Short stature	Short stature	Short stature
Medical history	No Characteristics	Asthma	No Characteristics
Family history	Mother's height: 143 cm Father's height: 165 cm Target height: 160.5 cm (-2.2 SDS) SHOX deletion in mother	Mother's height: 150.8 cm Father's height: 151.6 cm Target height: 157.7 cm (-2.5 SDS) SHOX deletion in father	Mother's height: 150.8 cm Father's height: 151.6 cm Target height: 144.7 cm (-2.8 SDS) SHOX deletion in father and brother
Height (SDS)	101 cm (-3.4)	89.3 cm (-2.85)	75 cm (-2.4)
Weight (SDS)	16.4 kg (-2.02)	16 kg (-0.03)	9.3 kg (-1.33)
BMI SDS	0.4	2.7	0.01
Sitting Height/Height (Percentile)	0.59 (>95 p)	0.61 (>95 p)	0.58 (>95 p)
Mesomelia	None	None	None
Madelung deformity	Yes	Yes	None
Bone Age (SDS)	4 years 6 months (-2.08)	2 years (-2.3)	14 months (-1.2)
IGF-1 (ug/L)	198 (22-208)	79.4 (<15-129)	83.9 (18.2-172)
Growth velocity before treatment	4.4 cm/year	4.68 cm/year	4.96 cm/year
Peak GH response (ng/ml)	6.33	8.7	5.69
rhGH dose rhGH period	50 mcg/kg/day 2 years 10 months	25 mcg/kg/day 3 years 5 months	35 mcg/kg/day 11 months
First Year Growth velocity after treatment	9.19 cm/year	10.9 cm/year	9.9 cm/year
Genetic analysis	Deletion of 266 Kb with 2 OMIMs in Xp22.33 region	SHOX deletion at locus Yp11.3	CNV gain with 15 OMIM genes of 1.4MB on the X chromosome

Result

Most cases with *SHOX* haploinsufficiency are misdiagnosed as idiopathic or familial short stature. In these cases, body disproportion and wrist radiography should be investigated carefully. *SHOX* deficiency should be considered especially if limb shortness and madelung deformity are present. rhGH treatment is a safe and effective option for improving final height in children with *SHOX* deficiency.